In last trading session, BioNTech SE ADR (NASDAQ:BNTX) saw 1.18 million shares changing hands with its beta currently measuring 1.28. Company’s recent per share price level of $92.34 trading at $0.26 or 0.28% at ring of the bell on the day assigns it a market valuation of $22.20B. That closing price of BNTX’s stock is at a discount of -42.4% from its 52-week high price of $131.49 and is indicating a premium of 17.12% from its 52-week low price of $76.53.
For BioNTech SE ADR (BNTX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.50. Splitting up the data highlights that, out of 13 analysts covering the stock, 2 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 9 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
BioNTech SE ADR (NASDAQ:BNTX) trade information
Upright in the green during last session for gaining 0.28%, in the last five days BNTX remained trading in the red while hitting it’s week-highest on Monday, 05/12/25 when the stock touched $92.34 price level, adding 5.28% to its value on the day. BioNTech SE ADR’s shares saw a change of -18.96% in year-to-date performance and have moved -2.57% in past 5-day. BioNTech SE ADR (NASDAQ:BNTX) showed a performance of -6.73% in past 30-days.
Wall Street analysts have assigned a consensus price target of 129.5 to the stock, which implies a rise of 28.69% to its current value. Analysts have been projecting 125 as a low price target for the stock while placing it at a high target of 134. It follows that stock’s current price would drop -35.37% in reaching the projected high whereas dropping to the targeted low would mean a loss of -35.37% for stock’s current value.
BioNTech SE ADR (BNTX) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -25.87% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -100.36% while estimates for its earnings growth in next 5 years are of -20.96%.
BioNTech SE ADR (NASDAQ:BNTX)’s Major holders
BAILLIE GIFFORD & CO is the top institutional holder at BNTX for having 8.28 million shares of worth $665.08 million. And as of 2024-06-30, it was holding 3.4425 of the company’s outstanding shares.
The second largest institutional holder is PRIMECAP MANAGEMENT CO/CA/, which was holding about 4.79 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.9922 of outstanding shares, having a total worth of $384.89 million.
On the other hand, VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund and iShares Trust-iShares Biotechnology ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024, the former fund manager was holding 2.27 shares of worth $209.7 million or 0.94% of the total outstanding shares. The later fund manager was in possession of 1.04 shares on Mar 31, 2025, making its stake of worth around $96.22 million in the company or a holder of 0.43% of company’s stock.
